先前暴露于贝兰他单抗马弗多汀影响多发性骨髓瘤患者使用Idecabtagene Vicluecel的结果。

IF 7.4 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2025-05-13 DOI:10.1182/bloodadvances.2024015648

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Fenghuang Zhan, Eric R Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.